SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017592
Filing Date
2022-11-14
Accepted
2022-11-14 08:00:37
Documents
77
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20220930x10q.htm   iXBRL 10-Q 1982466
2 EX-31.1 btai-20220930xex31d1.htm EX-31.1 17384
3 EX-31.2 btai-20220930xex31d2.htm EX-31.2 17603
4 EX-32.1 btai-20220930xex32d1.htm EX-32.1 10364
5 EX-32.2 btai-20220930xex32d2.htm EX-32.2 8797
6 GRAPHIC btai-20220930x10q006.jpg GRAPHIC 74360
  Complete submission text file 0001558370-22-017592.txt   7304192

Data Files

Seq Description Document Type Size
7 EX-101.SCH btai-20220930.xsd EX-101.SCH 45407
8 EX-101.CAL btai-20220930_cal.xml EX-101.CAL 45060
9 EX-101.DEF btai-20220930_def.xml EX-101.DEF 182470
10 EX-101.LAB btai-20220930_lab.xml EX-101.LAB 430905
11 EX-101.PRE btai-20220930_pre.xml EX-101.PRE 341517
71 EXTRACTED XBRL INSTANCE DOCUMENT btai-20220930x10q_htm.xml XML 1076133
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 221380409
SIC: 2834 Pharmaceutical Preparations